Azathioprine News and Research

RSS

Azathioprine is an immunosupressant used in organ transplantation, autoimmune disease such as rheumatoid arthritis or inflammatory bowel disease such as Crohn's disease and ulcerative colitis. It is a pro-drug, converted in the body to the active metabolites 6-mercaptopurine and 6-thioinosinic acid.

Plant-based diets trigger remission in Sjögren's syndrome and lupus cases

Three case studies show women with autoimmune diseases achieving symptom remission through plant-based diets, suggesting potential for dietary interventions in chronic disease management.

28 Feb 2024

Two new practice parameters offer recommendations for treating anaphylaxis and atopic dermatitis

Two new practice parameters from the Joint Task Force for Practice Parameters (JTFPP) offer evidence-based recommendations for the diagnosis and management of anaphylaxis and atopic dermatitis (AD) in pediatric and adult patients.

18 Dec 2023

Charting the future of IBD treatment: From immune modulators to microRNA therapies

In a recent study published in the journal eGastroenterology, researchers delved into the latest therapeutic strategies for managing inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The paper discusses emerging treatments ranging from immune-modulating drugs and biologics to novel approaches like microRNA upregulators and stem cell therapies, highlighting the need for precision medicine in IBD care.

8 Nov 2023

The standard of care and recent advancements in the control of skin inflammation

Researchers discuss current therapeutic interventions for atopic dermatitis in children and adolescents.

21 Aug 2023

Are inflammatory bowel disease patients more at risk of colorectal cancer?

Researchers analyzed data from a large cohort of inflammatory bowel disease patients and looked at the risk and frequency of colorectal cancer.

9 Aug 2023

Investigating the impact of COVID-19 vaccinations in immunocompromised adult patients

In a recent study posted to the medRxiv* preprint server, researchers assessed the impact of third and fourth coronavirus disease 2019 (COVID-19) vaccination doses on immunity against COVID-19 among immunocompromised adult patients.

9 Mar 2023

UT Southwestern physicians outline the risks of pregnancy in women with rheumatic disease

Pregnant women with active rheumatic disease carry a higher risk of adverse outcomes than the general population including hypertension, preeclampsia, higher cesarean section rate, small for gestational aged infants, preterm delivery, and fetal loss. To

19 Jul 2022

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Researchers assessed the risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immunomodulatory therapies.

13 Jun 2022

Study compares heterologous and homologous third vaccination in kidney transplant recipients

A new study assesses the comparative neutralizing antibody level elicited by three mRNA vaccine doses to a heterologous COVID-19 vaccine regimen.

28 Feb 2022

Research supports the need for a 3rd mRNA COVID vaccine in patients taking immunosuppressants

New research posted to the medRxiv* preprint server finds patients with immune-mediated inflammatory diseases undergoing anti-TNF therapy had the greatest reduction of antibody levels three months after vaccination. In addition, they had weaker neutralization responses towards severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.

1 Feb 2022

Efficacy and safety of mRNA-based SARS-CoV-2 vaccination in immuno-compromised subjects

A team of researchers assessed the immune response after administering a SARS-COV-2 vaccine in immuno-compromised subjects who are potentially at an increased risk to experience severe COVID-19 and inadequate response to SARS-CoV2 vaccination.

17 Jan 2022

Withdrawing steroid treatment found to boost SARS-CoV-2 vaccine-induced immunity in kidney transplant recipients

In a new study, a team of researchers investigated the impact of the fourth dose of a vaccine against COVID-19 in kidney transplant recipients, who had not mounted a humoral immune response to three doses of vaccine.

11 Jan 2022

Results of high-impact clinical trials could affect kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented online at ASN Kidney Week 2021 November 4–November 7.

7 Nov 2021

Humoral and cellular response to COVID-19 vaccines in patients with IBD

A new study published in the preprint server medRxiv* aimed to evaluate the humoral and cellular response to COVID-19 vaccine in patients with IBD undergoing biologic or immunomodulatory therapy.

17 Sep 2021

SARS-CoV-2 inhibited by pyrimidine biosynthesis inhibitors in conjunction with nucleoside analogs

In an effort to hasten the research on identifying antiviral drugs for SARS-CoV-2 infection, researchers from the U.S. and Switzerland performed extensive drug screening for antiviral activity using live virus infection in human respiratory cells. As a result, they identified a set of possible drug candidates that could potentially be tested in clinical trials.

30 Jun 2021

Commonly-prescribed drug for IBD blunts COVID-19 vaccine response

People who take a commonly-prescribed drug for inflammatory bowel disease (IBD) should not assume they are protected after a first dose of COVID-19 vaccine, after a large-scale study found many had poor antibody responses.

26 Apr 2021

Novel compound shows promise for ANCA-associated vasculitis

ANCA-associated vasculitis (AAV) is a systemic disease involving the formation of special autoantibodies (so-called anti-neutrophil cytoplasmic antibodies/ANCA) and vascular inflammation.

8 Jun 2020

Work in progress on medicine for treatment of ulcerative colitis

IKBFU center for clinical research scientists have participated in the international VARSITY clinical research. It's the world's first research aimed at finding the most effective drug among anti-inflammatory ones for the treatment of ulcerative colitis.

28 Oct 2019

Atopic dermatitis found to be highly prevalent among adults in the U.S.

As many as 16.5 million adults in America suffer from a skin disease known as atopic dermatitis, an inflammatory disease that results in red, itchy skin.

30 Oct 2018

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.

22 Oct 2018